[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].

Abstract

UNLABELLED:

Intradetrusor injection of botulinum toxin is one of the second-line therapy of neurologenic detrusor overactivity.

GOAL OF THE STUDY:

In 26% to 66% of the cases, intradetrusor injection of botulinum toxin is inefficient in order to reduce overactive bladder symptoms and/or overactive detrusor. The objective of this study is to determine whether it exists a link between the efficacy of the first IDBT and the length of neurological detrusor overactivity symptoms.

METHODS:

Retrospective study on 79 patients which have a first intradetrusor injection of botulinum toxin between January 2001 and December 2013. Inclusion criteria were patients older than 18 and having neurological detrusor overactivity.

RESULTS:

There is no significant difference of intradetrusor injection of botulinum toxin efficacy according to duration of urinary symptoms in the general neurologigal population (multiple sclerosis, spinal cord injury, spinal cord compression, ischemic pathology, infectious pathology) with the mean age being 46 years. On the contrary, the length of evolution of neurological detrusor overactivity symptoms before the intradetrusor botox injection therapy and the efficiency of the first intradetrusor injection of botulinum toxin seem to be correlated with negative results in patients with multiple sclerosis.

CONCLUSIONS:

The duration of urinary symptoms is a predictive factor of primary failure of intradetrusor injection of botulinum toxin in multiple sclerosis patients, in univariate analysis.

• Authors: M Lacout, A Guinet-Lacoste, M Popoff, D Verollet, F Lebreton, G Amarenco
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 25 Issue 11 Pg. 642-8 (Sep 2015) ISSN: 1166-7087 [Print] France
• Vernacular Title: Ancienneté de la neurovessie et efficacité d'une première injection de toxine botulique intradétrusorienne.
• PMID: 26094097 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Chemical References

• Acetylcholine Release Inhibitors
• Botulinum Toxins, Type A

Topics

• Acetylcholine Release Inhibitors (therapeutic use)
• Administration, Intravesical
• Adult
• Botulinum Toxins, Type A (administration & dosage)
• Female
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Treatment Outcome
• Urinary Bladder, Neurogenic (drug therapy)
• Urinary Bladder, Overactive (drug therapy)